FACT SHEET

Values as of October 31, 2026

KEY FACTS

FUND MANAGER	Fund box SGOIC
ISIN	PTFXOPIM0009; PTFXOQIM0008
INCEPTION DATE	NA
MATURITY DATE	NA
CUSTODIAN BANK	Bison Bank, S.A.
AUDITOR	Mazars & Associados, SROC
SUBSCRIPTION FEE	1,125%
MANAGEMENT FEE	0,5%
UNIT CLASSES	Class A; Class B
PRICE	Class A: 10,000 €; Class B: 10,000 €
MIN. INVESTMENT	Class A: 100,000 €; Class B: 100,000 €
SUBSCRIBED CAPITAL	500 000 €
SUBSCRIPTION PERIOD	Up to 09/01/2028

Initial Target Capital:

20 000 000 €

Investments Made:

No investments made to date

Fund Overview:

Private equity fund fully eligible under the Golden Visa program, focused on investments in healthcare innovation (medtech & biotech).

FUND HIGHLIGHTS

- RYSE Golden Opportunities Fund is a Portuguese private equity fund fully eligible under the Golden Visa program, focused on investments in healthcare innovation (medtech & biotech).
- Portugal is rapidly establishing itself as a European hub for med-tech and bio-tech, supported by strong public policies, EU-aligned frameworks, and a growing innovation ecosystem, including nationwide initiatives led by the Serviço Nacional de Saúde and EU-backed programs such as Portugal 2030 and the Recovery and Resilience Plan (PRR). The expansion of AI-driven med-tech, digital therapeutics, and biotechnology companies is reinforcing Portugal's attractiveness for healthcare investment.
- The Fund targets capital appreciation through equity investments, with proportional co-investments alongside partners when appropriate. The Fund is regulated by the Comissão do Mercado de Valores Mobiliários (CMVM) and managed by Fundbox SGOIC, with Ryse Asset Management acting as anchor investor, bringing sector-focused investment expertise and a multidisciplinary team with a strong track record in healthcare innovation, clinical development, and technology licensing.
- The Fund has received its first investment, reaching 500 000 € in subscribed capital.

INVESTMENT PORTFOLIO

Investment Focus and Allocation

- Sector Focus: Healthcare, med-tech, and bio-tech, with an emphasis on scalable, technology-enabled, and clinically validated solutions.
- Direct Investments: Growth capital in Portuguese healthcare, med-tech, and bio-tech companies.
- Indirect Investments: Selective exposure via RYSE Special Opportunities Fund I LP (UK).
- Geographic Allocation: Up to 60% in Portuguese companies and up to 40% in OECD-based companies or funds.

CONTACTS

FundBox

Yuliya Tovstolyak
Chief Investor Relations Officer
Investor Relations
T +351 21 310 36 20
investors@fundbox.pt

Issued and approved by FundBox SGOIC "FundBox" is a registered trade mark of FundBox Holdings SA and a trading name for a Comissão de Mercado de Valores Mobiliários (CMVM) regulated entities, FundBox SGOIC. The Fund is registered with CMVM under #2434. This document is provided to give an indication of the investment and does not constitute an offer or invitation to sell or buy any securities in any fund managed by us nor a solicitation to purchase securities in any company or investment product. It does not form part of any contract for the sale or purchase of any investment. The information contained in this document is for guidance only and does not constitute financial advice. The Fund price is calculated on a net asset value basis, which is the total value of all assets in the portfolio including any income and expense accruals. Please note that all FundBox funds carry some degree of risks which may have an adverse effect on the future value of your investment. Any offering is made only pursuant to the relevant offering document, and the relevant subscription/application forms, all of which must be read in their entirety. No offer to purchase units will be made or accepted prior to receipt by the offeree of these documents, and the completion of all appropriate documentation. Use or rely on this information at your own risk. Independent professional advice should always be sought before making an investment decision as not all investments are suitable for all investors.